本次减持计划实施前，辰欣药业股份有限公司（以下简称"公司"或"辰欣 药业"）持股 5%以上股东石家庄四药有限公司（以下简称"石四药"）持有辰欣 药业无限售流通股份 27,661,441 股，占辰欣药业总股本的 6.11%。前述股份来 源为石四药通过协议转让取得的股份。 减持计划的主要内容 石四药拟于自本公告披露之日起满 15 个交易日后的 3 个月内，根据市场情 况，做出适当减持安排。石四药拟通过集中竞价交易方式减持，在任意连续 90 日内，减持股份的数量不超过 4,527,000 股，减持比例不超过公司总股本的 1%。 在上述减持计划实施期间，公司发生增发、派息、送股、资本公积转增股本、配 股等除权除息事项，石四药将对减持计划进行相应调整。 证券代码：603367 证券简称：辰欣药业 公告编号：2025-047 辰欣药业股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 持股 5%以上大股东持股的基本情况 | 股东名称 | 石家庄四药有限公司 | | ...

每经AI快讯，8月29日，辰欣药业（603367）(603367.SH)公告称，公司持股5%以上股东石家庄四药有 限公司(简称"石四药")拟通过集中竞价交易方式减持，在任意连续90日内，减持股份的数量不超过 4,527,000股，减持比例不超过公司总股本的1%。减持期间为自公告披露之日起满15个交易日后的3个月 内。减持原因是资金需求。 ...

Financial Performance - The company reported a total revenue of 1.74 billion yuan for the first half of 2025, a decrease of 15.97% year-on-year [1] - The net profit attributable to shareholders was 229 million yuan, down 15.23% compared to the previous year [1] - The gross margin was 56.16%, a decline of 2.74% year-on-year, while the net margin increased slightly to 13.29%, up 0.56% [1] - In Q2 2025, total revenue was 820 million yuan, a decrease of 11.07% year-on-year, and net profit was 85.6 million yuan, down 20.33% [1] Key Financial Ratios - The company's return on invested capital (ROIC) was 8.01%, indicating average capital returns [3] - The historical median ROIC since the company went public is 11.34%, with the lowest recorded ROIC at 6.02% in 2022 [3] - The company’s net profit margin for the previous year was 12.93%, suggesting a high added value for its products or services [3] Cost Management - Total selling, administrative, and financial expenses amounted to 563 million yuan, accounting for 32.36% of revenue, a decrease of 7.09% year-on-year [1] - The company has a significant accounts receivable situation, with accounts receivable to profit ratio reaching 135.84% [3] Shareholder Information - The largest fund holding in the company is the Multi-Strategy LOF, with a current scale of 90 million yuan and a recent net value of 1.4275, down 1.94% from the previous trading day [4] - The fund has seen a 22.95% increase over the past year [4]

Group 1 - The core viewpoint of the news is that Chenxin Pharmaceutical (603367.SH) has reported significant institutional investment, with 17 institutional investors holding a total of 246 million shares, representing 54.39% of the company's total equity as of August 27, 2025 [1] - The top ten institutional investors collectively hold 54.15% of the shares, with an increase of 2.08 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, four new public funds have been disclosed this period, including Rongtong Health Industry Flexible Allocation Mixed A/B and others [2] - Four public funds were not disclosed in this period compared to the previous quarter, including Dachen Multi-Strategy Mixed (LOF) A and others [2]

Group 1 - The company announced a semi-annual distribution plan on August 27, 2025, proposing a cash dividend of 1.88 yuan per 10 shares, totaling approximately 85.12 million yuan [3][6] - The cash distribution represents 37.14% of the company's net profit, marking the 10th cumulative cash distribution since its listing [3][6] - The company reported a revenue of 1.74 billion yuan for the first half of 2025, a year-on-year decrease of 15.97%, and a net profit of 229 million yuan, down 15.23% year-on-year [1][2] Group 2 - In the pharmaceutical and biotechnology sector, 51 companies have announced their semi-annual distribution plans for 2025, with WuXi AppTec leading with a total cash distribution of 1 billion yuan [2][4] - The company experienced a net outflow of 77.08 million yuan in principal funds on August 27, with a total outflow of 177 million yuan over the past five days [2][5] - The company's dividend yield for the proposed distribution is 1.34% [3][6]

Group 1 - The stock price of Chenxin Pharmaceutical closed at 26.52 yuan on August 27, 2025, down 6.06% from the previous trading day [1] - The company reported a trading volume of 511 million yuan and a turnover rate of 4.14% on the same day [1] - Chenxin Pharmaceutical specializes in chemical pharmaceuticals, with products covering areas such as anti-infection, anti-tumor, and digestive system medications [1] Group 2 - The company announced a cash dividend of 1.88 yuan (including tax) per 10 shares to all shareholders, with a total distribution amount expected to be 85.12 million yuan [1] - According to the 2025 semi-annual report, the company achieved an operating income of 1.74 billion yuan and a net profit attributable to shareholders of 229 million yuan in the first half of the year, representing a year-on-year decline of 16.0% and 15.2%, respectively [1] Group 3 - On August 27, the net outflow of main funds was 94.24 million yuan, with a cumulative net outflow of 247 million yuan over the past five days [1]

证券代码：603367 证券简称：辰欣药业 公告编号：2025-039 会议审议通过了如下议案： 经审议，公司监事会认为：公司 2025 年半年度报告及摘要的编制和审议程 序符合法律、法规、《公司章程》和公司内部管理制度的各项规定；公司 2025 年半年度报告及摘要的内容与格式符合中国证券监督管理委员会和上海证券交 易所的各项规定，能够公允地反映公司报告期内的财务状况和经营成果。监事会 及全体监事保证公司 2025 年半年度报告及摘要所披露的信息真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性依法承担法律责任。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《辰 欣药业股份有限公司 2025 年半年度报告》《辰欣药业股份有限公司 2025 年半年 度报告摘要》。 表决结果：3 票同意，0 票反对，0 票弃权。 为加大投资者回报，分享经营成果，提振投资者持股信心，根据《上海证券 交易所股票上市规则》《上市公司监管指引第 3 号——上市公司现金分红》《公 司章程》等有关法律法规的规定，公司制定了 2025 年度中期利润分配（半年度 利润 ...

Group 1 - The company, Chenxin Pharmaceutical Co., Ltd., is convening its second extraordinary general meeting of shareholders in 2025 on September 16, 2025 [4][6] - The meeting will be held at the company's office located at No. 16 Tongji Road, High-tech Zone, Jining City, Shandong Province, starting at 1:30 PM [4][7] - Shareholders can vote through both on-site and online methods, utilizing the Shanghai Stock Exchange's network voting system [2][5] Group 2 - The voting period for the online system will be from 9:15 AM to 3:00 PM on the day of the meeting [4][5] - Shareholders must register in advance to attend the meeting, with specific requirements for both corporate and individual shareholders [6][7] - The company has confirmed that there are no related shareholders that need to abstain from voting on the agenda items [4]

辰欣药业股份有限公司章程 辰欣药业股份有限公司 公司章程 第八章 通知与公告 第十章 修改章程 第十一章 附则 2 （2025 年 8 月） 1 辰欣药业股份有限公司章程 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第六章 经理及高级管理人员 第七章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第一节 通知 第二节 公告 第九章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 辰欣药业股份有限公司章程 第一章 总则 1.1 为维护辰欣药业股份有限公司（以下简称"公司"）、股东、职工和 债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》（以 ...

辰欣药业股份有限公司 内部审计制度 （2025 年 8 月） 1 / 10 第一章 总则 第一条 为规范辰欣药业股份有限公司（以下简称"公司"）内部审计工作，保证内部审计部 门依法行使职权，提高内部审计工作质量，保护投资者合法权益，根据《中华人民共和国审计 法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范 运作》等法律、法规、规范性文件和《辰欣药业股份有限公司章程》（以下简称《" 公司章程》"） 的规定并结合公司实际情况，制定本制度。 第二条 本制度所称内部审计工作，是指公司内部审计机构或人员，对公司内部控制和风险 管理的有效性、财务信息的真实性和完整性以及经营活动的效率和效果等开展的一种评价活动。 本制度所称内部控制，是指公司董事会、高级管理人员及其他有关人员为实现下列目标而 提供合理保证的过程： 1、遵守国家法律、法规、规章及其他相关规定； 2、提高公司经营的效率和效果； 3、保障公司资产的安全； 4、确保公司信息披露的真实、准确、完整和公平。 第三条 公司内部审计遵循"独立、客观、公正、保密"原则。 第四条 公司董事会对内部控制制度的建立健全和有效实施负责，重要的 ...